


ART 34 AMEND X-15110 PCT

REPLACEMENT SHEET

-430-

R^8 represents hydrogen, halo, (C_1-C_6) alkyl, hydroxy (C_1-C_6) alkyl, (C_1-C_4) alkyl - (C_1-C_6) alkoxy, COR¹² wherein R^{12} represents methoxy, ethoxy, hydroxymethyl, or methoxymethyl; (C_3-C_7) cycloalkyl, aryl or substituted aryl.

5 37. A novel compound of Formula I:




Formula I


wherein,

10

"A" represents




"B" represents



15

and "C" represents



X and Y together represent $-CH_2-CH_2-$, $-CH_2-O-$, or $-O-CH_2-$;

20

"-----" represents a double bond;

AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET

-431-

- R^1 represents halo, amino, oxo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, hydroxymethyl, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, $SO_2NR^9R^{10}$ wherein R^9 represents (C_1-C_6) alkyl, (C_1-C_4) alkyl- (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, aryl, (C_1-C_4) alkyl-aryl, heterocycle and R^{10} represents hydrogen or methyl, or R^9 and R^{10} together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; $NH SO_2R^{11}$ wherein R^{11} represents amino, (C_1-C_6) alkyl, halo (C_1-C_6) alkyl, (C_1-C_6) alkoxy, (C_3-C_7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; $NHCOR^{12}$ wherein R^{12} represents H, amino, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, hydroxy (C_1-C_6) alkyl, (C_1-C) alkyl- (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl, NH-methylamine, NH-dimethylamine, NH-ethylamine, or heterocycle; COR^{12} wherein R^{12} represents H, amino, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, or hydroxy (C_1-C_6) alkyl; OR^{14} wherein R^{14} represents (C_1-C) alkyl-heterocycle; or a (C_1-C_4) alkyl-heterocycle represented by the formula:



15

provided that where "C" represents an aryl group then R^1 is other than oxo.;
further provided that where "C" represents a benzo-fused heterocycle then R^1
may also represent hydrogen;

- R^2 represents hydrogen, halo, hydroxy, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, or (C_1-C_4) alkyl-heterocycle;

R^3 represents hydrogen, halo, or (C_1-C_6) alkyl;

R^4-R^7 each independently represent hydrogen, hydroxy, halo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, or OR^{14} wherein R^{14} represents (C_1-C_4) alkyl-aryl, (C_1-C_4) alkyl-substituted aryl, (C_1-C_4) alkyl-heterocycle, or (C_1-C_4) alkyl- (C_3-C_7) cycloalkyl;

- R^8 represents hydrogen, halo, (C_1-C_6) alkyl, hydroxymethyl, (C_1-C_4) alkyl- (C_1-C_6) alkoxy, or COR^{12} wherein R^{12} represents (C_1-C_6) alkoxy, (C_3-C_7) cycloalkyl, phenyl, or substituted aryl;

- further provided that where C represents a phenyl ring and R^1 represents halo then
at least one of R^2 and R^3 is other than hydrogen, (C_1-C_6) alkyl, aryl, substituted aryl, (C_1-C_4) alkyl-aryl, (C_1-C_4) alkyl-substituted aryl, CHF_2 , or CF_3 ; and

AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET


-432-

further provided that where C represents a six-membered ring and R¹ represents amino or NHCOCH₃ and R² and R³ are each hydrogen, then R¹ is not bound at the 4-position of said six-membered ring,

or a pharmaceutically acceptable salt thereof.

5

38. The compound according to Claim 37 wherein "C" represents a phenyl ring and R¹ represents SO₂NR⁹R¹⁰ wherein R⁹ represents (C₁-C₆)alkyl, (C₁-C₄)alkyl-, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, aryl, (C₁-C₄)alkyl-aryl, heterocycle and R¹⁰ represents hydrogen or methyl, or R⁹ and R¹⁰ together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; NH SO₂R¹¹ wherein R¹¹ represents amino, (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₃-C₇)cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; NHCOR¹² wherein R¹² represents H, amino, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl-(C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, NH-methylamine, NH-dimethylamine, NH-ethylamine, or heterocycle; COR¹² wherein R¹² represents H, amino, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or hydroxy(C₁-C₆)alkyl; OR¹⁴ wherein R¹⁴ represents (C₁-C₆)alkyl-heterocycle; or a (C₁-C₄)alkyl-heterocycle represented by the formula:



- 20 or a pharmaceutically acceptable salt thereof.

39. A compound according to any one of Claims 37 and 38 wherein when R¹ represents NH SO₂R¹¹, R¹¹ represents methyl, ethyl, propyl, isopropyl, butyl, or 2-methyl propyl.

- 25 40. The compound according to Claim 39 wherein R¹¹ represents methyl.

41. A compound according to any one of Claims 37 - 40 wherein R² represents hydrogen or (C₁-C₄)alkyl-heterocycle.

42. The compound according to Claim 41 wherein R² represents hydrogen.

- 30 43. A compound according to any one of Claims 37 - 42 wherein R³ represents hydrogen.

44. A compound according to any one of claims 37, 41-43 wherein "C" represents a benzofused heterocycle having a non-hydrogen substituent at at least one of


AMENDED SHEET

ART 34 AND X-15110 PCT

REPLACEMENT SHEET

-433-

R1-R3, wherein said benzofused heterocycle having a non-hydrogen substituent is given by the following:



45. A compound according to any one of Claims 37-44 wherein R⁴ and R⁶ each independently represent hydrogen, halo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or OR¹⁴ wherein R¹⁴ represents (C₁-C₄)alkyl-aryl, (C₁-C₄)alkyl-substituted aryl, (C₁-C₄)alkyl-heterocycle, or (C₁-C₄)alkyl-(C₃-C₇)cycloalkyl.


46. A compound according to any one of Claim 37- 45 wherein R⁵ and R⁷ each independently represent hydrogen, hydroxy, halo, (C₁-C₆)alkyl, or (C₁-C₆)alkoxy.

47. A compound according to any one of Claims 37-46 wherein R⁸ represents hydrogen, halo, (C₁-C₆)alkyl, (C₁-C₄)alkyl -(C₁-C₆)alkoxy, or (C₃-C₇)cycloalkyl.

48. The compound according to Claim 47 wherein R⁸ represents halo (C₁-C₆)alkyl, (C₁-C₄)alkyl -(C₁-C₆)alkoxy.


49. The compound according to Claim 47 wherein R⁸ represents hydrogen.

50. A compound of the formula



or a pharmaceutically acceptable salt thereof.

51. A compound of the formula



or a pharmaceutically acceptable salt thereof.

AMENDED SHEET


X-15110 PCT

REPLACEMENT SHEET

ART 34 AMBT


-434-

52. A compound of the formula




or a pharmaceutically acceptable salt thereof.

5 53. A compound of the formula




or a pharmaceutically acceptable salt thereof.

10 54. A compound of the formula



or a pharmaceutically acceptable salt thereof.

15 55. A compound of the formula



or a pharmaceutically acceptable salt thereof.


20 56. A compound of the formula

AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET


-435-



or a pharmaceutically acceptable salt thereof.


57. A compound of the formula

5



or a pharmaceutically acceptable salt thereof.

58. A compound of the formula



10

or a pharmaceutically acceptable salt thereof.


59. A compound of the formula

X-15110 PCT

REPLACEMENT SHEET


ART 34 ADD!

-436-



or a pharmaceutically acceptable salt thereof.


60. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

61. A compound of the formula



10

or a pharmaceutically acceptable salt thereof.


62. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-437-



or a pharmaceutically acceptable salt thereof.


63. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

64. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.


65. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-438-




or a pharmaceutically acceptable salt thereof.

66. A compound of the formula



or a pharmaceutically acceptable salt thereof.

67. A compound of the formula



or a pharmaceutically acceptable salt thereof.


68. A compound of the formula

ART 34 AMDT

X-15110 PCT


REPLACEMENT SHEET

-439-



or a pharmaceutically acceptable salt thereof.


69. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

70. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.


71. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-440-



or a pharmaceutically acceptable salt thereof.


72. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

73. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.


74. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-441-



or a pharmaceutically acceptable salt thereof.


75. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

76. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.

77. A compound of the formula


AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET


ART 34 PCT

-442-



or a pharmaceutically acceptable salt thereof.


78. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

79. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.


80. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-443-



or a pharmaceutically acceptable salt thereof.


81. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

82. A compound of the formula




10 or a pharmaceutically acceptable salt thereof.

83. A compound of the formula

AMENDED SHEET


X-15110 PCT

REPLACEMENT SHEET

~~444~~

or a pharmaceutically acceptable salt thereof.


84. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

85. A compound of the formula



10 or a pharmaceutically acceptable salt thereof.


86. A compound of the formula

AMENDED SHEET

X-15110 PCT


REPLACEMENT SHEET

-445-



or a pharmaceutically acceptable salt thereof.


87. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

88. A compound of the formula




10 or a pharmaceutically acceptable salt thereof.

89. A compound of the formula

X-15110 PCT


REPLACEMENT SHEET

-446-



or a pharmaceutically acceptable salt thereof.


90. A compound of the formula



5

or a pharmaceutically acceptable salt thereof.

91. A compound of the formula



or a pharmaceutically acceptable salt thereof.

10


92. A compound of the formula

AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET

-447-



or a pharmaceutically acceptable salt thereof.

93. A method of treating a physiological disorder susceptible to
- 5 mineralocorticoid or glucocorticoid receptor modulation wherein said disorder is selected from the group consisting of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction,
- 10 Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varices, Addison's Disease, muscle weakness, increased melanin
- 15 pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis
- 20 nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia,
- 25 cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative

AMENDED SHEET

X-15110 PCT

REPLACEMENT SHEET

-448-

- dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid,
- 5 dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multiple sclerosis., comprising administering to a patient in need thereof an effective amount of a
- 10 novel compound of Formula I according to claim 37.

94. The method according to claim 93, wherein said disorder is diastolic or systolic congestive heart failure, inflammation, rheumatoid arthritis, an autoimmune disorder, asthma, or chronic obstructive pulmonary disease

- 15 95. The method according to claim 94, wherein said disorder is diastolic or systolic congestive heart failure or rheumatoid arthritis.

96. A method of modulating a steroid hormone nuclear receptor , wherein said steroid nuclear receptor is the mineralocorticoid receptor or the glucocorticoid receptor , comprising administering to a patient in need thereof an effective amount of a compound of Formula I according to Claim 37.

- 20 97. A pharmaceutical composition comprising an effective amount of a compound of Formula I according to Claim 37 in combination with a pharmaceutically acceptable carrier.

- 25 98. The use of a compound of Formula I according to Claim 37 for the manufacture of a medicament for the treatment of diastolic or systolic congestive heart failure or rheumatoid arthritis.

30

35

AMENDED SHEET


X-15110 PCT

REPLACEMENT SHEET

-449-

ABSTRACT

- The present invention relates to methods of treating pathological disorders
5 susceptible to steroid hormone nuclear receptor modulation comprising administering to a
patient in need thereof an effective amount of a compound of the formula:



Formula I

- 10 or a pharmaceutically acceptable salt thereof. In addition, the present invention provides
novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable
salts thereof, as well as pharmaceutical compositions which comprise as an active
ingredient a compound of Formula I.

15

AMENDED SHEET